The amount of the transaction, conducted by Chiesi’s UK-based subsisdiary, was not disclosed. The seller was venture capital firm Sunstone Capital.
Zymenex is a biopharmaceutical group focused on research and development of innovative biologic therapeutics for the treatment of rare and life threatening genetic diseases.
The acquisition includes LamazymTM (rhLAMAN), a phase III recombinant enzyme indicated for use to treat patients suffering from alpha-Mannosidosis, as well as other early stage compounds. Led by Ugo Di Francesco, CEO, Chiesi will gradually integrate Zymenex into its R&D structure and retain the Zymenex and LamazymTM brands.
Founded in 1935, Chiesi Farmaceutici currently has 25 affiliates worldwide and markets its therapeutics in over 60 countries. It has manufacturing plants in Parma, Blois (France) and Santana de Parnaiba (Brazil), and R&D centers in Parma, Paris, Rockville (USA) and Chippenham (UK). At the end of 2012, the Chiesi Group had over 3,800 employees, more than 350 of whom are dedicated to R&D.